KR102000332B1 - 간내 담즙정체성 질환의 치료 - Google Patents

간내 담즙정체성 질환의 치료 Download PDF

Info

Publication number
KR102000332B1
KR102000332B1 KR1020167025636A KR20167025636A KR102000332B1 KR 102000332 B1 KR102000332 B1 KR 102000332B1 KR 1020167025636 A KR1020167025636 A KR 1020167025636A KR 20167025636 A KR20167025636 A KR 20167025636A KR 102000332 B1 KR102000332 B1 KR 102000332B1
Authority
KR
South Korea
Prior art keywords
mbx
intrahepatic
disease
pharmaceutical composition
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167025636A
Other languages
English (en)
Korean (ko)
Other versions
KR20160125424A (ko
Inventor
폴 뷰즈
찰스 에이 맥위어터
Original Assignee
사이머베이 쎄라퓨틱스, 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사이머베이 쎄라퓨틱스, 인코퍼레이티드 filed Critical 사이머베이 쎄라퓨틱스, 인코퍼레이티드
Publication of KR20160125424A publication Critical patent/KR20160125424A/ko
Application granted granted Critical
Publication of KR102000332B1 publication Critical patent/KR102000332B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020167025636A 2014-03-20 2015-03-19 간내 담즙정체성 질환의 치료 Active KR102000332B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461968037P 2014-03-20 2014-03-20
US61/968,037 2014-03-20
PCT/US2015/021502 WO2015143178A1 (en) 2014-03-20 2015-03-19 Treatment of intrahepatic cholestatic diseases

Publications (2)

Publication Number Publication Date
KR20160125424A KR20160125424A (ko) 2016-10-31
KR102000332B1 true KR102000332B1 (ko) 2019-07-15

Family

ID=52808186

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167025636A Active KR102000332B1 (ko) 2014-03-20 2015-03-19 간내 담즙정체성 질환의 치료

Country Status (32)

Country Link
US (5) US9486428B2 (enExample)
EP (1) EP3119384B1 (enExample)
JP (1) JP6568577B2 (enExample)
KR (1) KR102000332B1 (enExample)
CN (1) CN106102734B (enExample)
AU (1) AU2015231232B2 (enExample)
BR (1) BR112016020260A8 (enExample)
CA (1) CA2941401C (enExample)
CL (1) CL2016002338A1 (enExample)
CY (1) CY1120927T1 (enExample)
DK (1) DK3119384T3 (enExample)
EA (1) EA032358B1 (enExample)
ES (1) ES2701094T3 (enExample)
FI (1) FIC20253004I1 (enExample)
FR (1) FR25C1031I1 (enExample)
HR (1) HRP20181914T1 (enExample)
HU (2) HUE041733T2 (enExample)
IL (1) IL247920B (enExample)
LT (2) LT3119384T (enExample)
MX (1) MX367478B (enExample)
NL (1) NL301338I2 (enExample)
NO (1) NO2025035I1 (enExample)
NZ (1) NZ724057A (enExample)
PH (1) PH12016501769A1 (enExample)
PL (1) PL3119384T3 (enExample)
PT (1) PT3119384T (enExample)
RS (1) RS57970B1 (enExample)
SI (1) SI3119384T1 (enExample)
SM (1) SMT201800690T1 (enExample)
UA (1) UA120756C2 (enExample)
WO (1) WO2015143178A1 (enExample)
ZA (1) ZA201606043B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0920170A2 (pt) 2008-10-17 2016-06-21 Metabolex Inc métodos para diminuir a quantidade de partículas ldl pequenas e densas e de níveis de triglicerídeos e ldl no sangue em um humano, e para identificar um indivíduo candidato para tratamento com um composto ou um sal, prodroga ou isômero do mesmo, composto ou um sal, prodroga ou isômero do mesmo, e método.
US10272058B2 (en) * 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
CN106163508A (zh) 2014-04-11 2016-11-23 西玛贝医药公司 Nafld和nash的治疗
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
UA125600C2 (uk) * 2017-09-26 2022-04-27 Сімабей Терапьютікс, Інк. Лікування холестатичного свербежу
MX2021005725A (es) * 2018-11-16 2021-07-21 Cymabay Therapeutics Inc Tratamiento de la obesidad y sus complicaciones.
CA3148602A1 (en) 2019-08-02 2021-02-11 Acelot, Inc. Small molecule drugs and related methods for treatment of diseases related to tdp-43, alpha-synuclein, huntingtin's protein and tau protein oligomer formation
US20210145775A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Treatment of intestinal barrier dysfunction and associated diseases
US20210145774A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Treatment of alcoholic liver disease
US20220241228A1 (en) 2021-02-01 2022-08-04 Cymabay Therapeutics, Inc. Treatment of cholangiopathies

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101993B1 (en) 1990-01-11 2006-09-05 Isis Pharmaceuticals, Inc. Oligonucleotides containing 2′-O-modified purines
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
EP0813539B1 (en) 1995-03-06 2006-05-24 Isis Pharmaceuticals, Inc. Improved process for the synthesis of 2'-o-substituted pyrimidines and oligomeric compounds therefrom
WO1997030067A1 (en) 1996-02-14 1997-08-21 Isis Pharmaceuticals, Inc. Sugar-modified gapped oligonucleotides
US5883109A (en) 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
US7981915B2 (en) * 2003-04-30 2011-07-19 Beth Israel Deaconess Medical Center Methods for modulating PPAR biological activity for the treatment of diseases caused by mutations in the CFTR gene
SG145752A1 (en) 2003-09-19 2008-09-29 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
SI1725234T1 (sl) 2004-03-05 2013-04-30 The Trustees Of The University Of Pennsylvania Postopki zdravljenja nepravilnosti ali bolezni povezanih s hiperlipidemijo in hiperholesterolemijo z minimiziranjem stranskih uäśinkov
JO3006B1 (ar) * 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
BRPI0920170A2 (pt) 2008-10-17 2016-06-21 Metabolex Inc métodos para diminuir a quantidade de partículas ldl pequenas e densas e de níveis de triglicerídeos e ldl no sangue em um humano, e para identificar um indivíduo candidato para tratamento com um composto ou um sal, prodroga ou isômero do mesmo, composto ou um sal, prodroga ou isômero do mesmo, e método.
SG183529A1 (en) 2010-03-30 2012-10-30 Novartis Ag Uses of dgat1 inhibitors
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
AU2014353246A1 (en) 2013-11-20 2016-06-16 Cymabay Therapeutics, Inc. Treatment of homozygous familial hypercholesterolemia
US20160279085A1 (en) 2013-11-20 2016-09-29 Cymabay Therapeutics, Inc. Treatment of Severe Hyperlipidemia
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
CN106163508A (zh) 2014-04-11 2016-11-23 西玛贝医药公司 Nafld和nash的治疗
HK1231380A1 (zh) 2014-06-26 2017-12-22 Cymabay Therapeutics, Inc. 严重高甘油三酯血症的治疗
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
UA125600C2 (uk) 2017-09-26 2022-04-27 Сімабей Терапьютікс, Інк. Лікування холестатичного свербежу
MX2021005725A (es) 2018-11-16 2021-07-21 Cymabay Therapeutics Inc Tratamiento de la obesidad y sus complicaciones.
EA202191379A1 (ru) 2018-11-16 2021-08-06 Саймабэй Терапьютикс, Инк. Комбинированное лечение nafld и nash

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. of clinical endocrinology & metabolism, Endocrine Society, US, 96(9), 2889-2897(2011.07.13.)
Proceedings of the National academy of sciences, 109(21), E1369-E1376(2012.04.25.)

Also Published As

Publication number Publication date
IL247920B (en) 2019-03-31
FIC20253004I1 (fi) 2025-07-31
MX2016012203A (es) 2017-01-19
BR112016020260A8 (pt) 2021-06-29
AU2015231232B2 (en) 2018-08-02
NZ724057A (en) 2018-09-28
HRP20181914T1 (hr) 2019-01-11
PH12016501769B1 (en) 2017-01-09
JP2017508817A (ja) 2017-03-30
LTPA2025529I1 (enExample) 2025-08-25
PT3119384T (pt) 2018-12-12
BR112016020260A2 (pt) 2017-08-15
US10828273B2 (en) 2020-11-10
US11406611B2 (en) 2022-08-09
SI3119384T1 (sl) 2018-12-31
CA2941401C (en) 2019-06-11
US20210023031A1 (en) 2021-01-28
US20150265560A1 (en) 2015-09-24
PL3119384T3 (pl) 2019-03-29
SMT201800690T1 (it) 2019-01-11
US9486428B2 (en) 2016-11-08
LT3119384T (lt) 2018-11-26
CN106102734B (zh) 2019-05-14
US9808436B2 (en) 2017-11-07
AU2015231232A1 (en) 2016-09-22
CN106102734A (zh) 2016-11-09
EP3119384A1 (en) 2017-01-25
US10220011B2 (en) 2019-03-05
UA120756C2 (uk) 2020-02-10
CY1120927T1 (el) 2019-12-11
CA2941401A1 (en) 2015-09-24
HUS2500033I1 (hu) 2025-09-28
ZA201606043B (en) 2018-05-30
RS57970B1 (sr) 2019-01-31
EP3119384B1 (en) 2018-09-12
HUE041733T2 (hu) 2019-05-28
WO2015143178A1 (en) 2015-09-24
JP6568577B2 (ja) 2019-08-28
EA032358B1 (ru) 2019-05-31
ES2701094T3 (es) 2019-02-20
EA201691887A1 (ru) 2017-03-31
FR25C1031I1 (fr) 2025-09-26
MX367478B (es) 2019-08-23
US20170014363A1 (en) 2017-01-19
NL301338I2 (nl) 2025-09-11
US20180036268A1 (en) 2018-02-08
PH12016501769A1 (en) 2017-01-09
NO2025035I1 (no) 2025-08-01
DK3119384T3 (en) 2018-12-03
US20190192459A1 (en) 2019-06-27
KR20160125424A (ko) 2016-10-31
CL2016002338A1 (es) 2017-04-21

Similar Documents

Publication Publication Date Title
KR102000332B1 (ko) 간내 담즙정체성 질환의 치료
US11596614B2 (en) Treatment of intrahepatic cholestatic diseases
US11224580B2 (en) Treatment of intrahepatic cholestatic diseases
HK1229212A1 (en) Treatment of intrahepatic cholestatic diseases
HK1229212B (en) Treatment of intrahepatic cholestatic diseases
HK1262698B (en) Seladelpar for the treatment of primary biliary cholangitis
HK1262698A1 (en) Seladelpar for the treatment of primary biliary cholangitis

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000